Tumor xenograft | Drug^{a} | Growth delay in control mice (days)^{b} | Growth delay in treated mice (days)^{b} | Growth delay index^{c} | % of optimal growth inhibition^{d} (days) | No. of complete regressions/ group | Duration of complete regressions in days^{e} |
---|---|---|---|---|---|---|---|
SCLC-61 | VP16-CDDP^{*} | 11 | 55 | 5 | 100 (6) | 6 /6 | 9 |
VP16-IFO | 11 | >77 | >7 | 100 (>6) | 7 /7 | >70 | |
CDDP-IFO | 8.5 | 29 | 3.5 | 98 (10) | 2 /6 | >33 | |
VP16-IFO-CDDP | 11 | >110 | >10 | 100 (>6) | 3 /3 | >70 | |
SCLC-100 | VP16-CDDP | 10.5 | 20 | 1.9 | 96 (9) | 1 /7 | 2 |
VP16-IFO | 9.5 | >82 | >8.6 | 100 (>13) | 5 /7 | >23 | |
CDDP-IFO | 7 | 18 | 2.5 | 100 (>8) | 2 /8 | 4 | |
VP16-IFO-CDDP | 7 | >63 | >9 | 100 (>8) | 7 /8 | >63 | |
SCLC-6 | VP16-CDDP | 6 | 8 | 1.3 | 78 (13) | 0 /7 | None |
VP16-IFO | 6 | 19 | 3.2 | 98 (15) | 0 /8 | None | |
CDDP-IFO | 6 | 23 | 3.8 | 98 (14) | 0 /8 | None | |
VP16-IFO-CDDP | 6 | 28 | 4.7 | 98 (14) | 0 /8 | None | |
SCLC-41 | VP16-CDDP^{*} | 14 | 31 | 2.2 | 100 (17) | 4 /7 | 6 |
VP16-IFO | 14 | 33 | 2.4 | 100 (17) | 6 /7 | 7 | |
CDDP-IFO | 8 | 15 | 1.9 | 89 (8) | 0 /7 | None | |
VP16-IFO-CDDP | 8 | 31 | 3.9 | 97 (10) | 2 /7 | >21 | |
SCLC-74 | VP16-CDDP | 6 | 11 | 1.8 | 67 (13) | 0 /5 | None |
VP16-IFO | 6 | 10 | 1.7 | 65 (13) | 0 /6 | None | |
CDDP-IFO | 6 | 11 | 1.8 | 65 (13) | 0 /6 | None | |
VP16-IFO-CDDP | 6 | 11 | 1.8 | 63 (12) | 0 /6 | None | |
SCLC-101 | VP16-CDDP^{*} | 15 | 16 | 1.1 | 48 (21) | 0 /6 | None |
VP16-IFO | 15 | 37 | 2.5 | 96 (14) | 1 /6 | 6 | |
CDDP-IFO | 14 | 38 | 2.7 | 95 (14) | 1 /8 | 6 | |
VP16-IFO-CDDP | 14 | 43 | 3.1 | 99 (13) | 3 /8 | 12 | |
SCLC-96 | VP16-CDDP | 16 | 26 | 1.6 | 72 (9) | 0 /6 | None |
VP16-IFO | 16 | 27 | 1.7 | 59 (22) | 1 /6 | 2 | |
CDDP-IFO | 16 | 24 | 1.5 | 68 (14) | 0 /8 | None | |
VP16-IFO-CDDP | 16 | 28 | 1.8 | 73 (16) | 0 /8 | None | |
SCLC-108 | VP16-IFO | 26 | 39 | 1.5 | 69 (20) | 2 /6 | 12 |
CDDP-IFO | 26 | 32 | 1.2 | 50 (23) | 0 /5 | None | |
VP16-IFO-CDDP | 26 | 38 | 1.5 | 52 (23) | 0 /6 | None |
^{a} VP16 was given at 12 mg/kg/day, days 1, 2, and 3; CDDP, 6 or
* 9 mg/kg, day 1; IFO, 90 mg/kg/day, days 1, 2, and 3.
^{b} Growth delays were calculated as the time in days required for an individual tumor to reach a 5-fold increase in volume and are expressed as median values.
^{c} Index of growth delay calculated as the ratio between the median growth delay in treated mice and in control mice.
^{d} Expressed as the median values; in parentheses, the day of observation of optimal growth inhibition.
^{e} Expressed as the median values; none indicates that no complete regression was obtained.